Dynamics and variability of regional mortality rates from liver and biliary tract diseases in the period from 2019 to 2021
https://doi.org/10.30629/0023-2149-2023-101-9-10-489-495
Abstract
Objective: to assess the variability and dynamics of mortality from liver and bile duct diseases in the regions of Russia for the period of 2019–2021. Materials and methods. Rosstat data on the number of deaths according to form C51 and on the average annual population by one-year age groups by gender and age were used. Standardized mortality rates (SMRs) were calculated for 12 causes of death related to liver and bile duct diseases and included in the Brief Nomenclature of Causes of Death of Rosstat (BNCD) for 82 regions of the Russian Federation. Results. The mean SMRs from all liver and bile duct diseases in 2020 (42.4 ± 11.9 per 100,000 population) and 2021 (42.8 ± 13.2) were higher than in 2019 (39.4 ± 11.4), with annual increases observed in 38 regions, decreases in 7, and mixed trends in 37. The contribution of liver diseases to all-cause mortality was 3.95 ± 0.91% in 2019, 3.65 ± 0.85% in 2020, and 3.26 ± 0.92% in 2021. The highest SMRs were registered for liver fibrosis and cirrhosis, while the lowest SMRs were for acute hepatitis. Considerable variability in SMRs was observed between regions in 2021: the maximum SMR for liver cancer was more than 14 times higher than the minimum, while for liver fibrosis and cirrhosis it was 25 times higher. Hypotheses explaining the reasons for these differences are discussed. Conclusions. Significant regional variability in SMRs does not allow for a stable trend towards reducing mortality from these causes to be identified.
About the Authors
I. V. Samorodskaya
National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of Russia
Russian Federation
Russian Federation
Samorodskaya Irina V.
101990, Moscow
T. E. Afanasenkova
Smolensk State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Afanasenkova Tatiana E.
214019, Smolensk
References
1. Asrani S.K., Devarbhavi H., Eaton J., Kamath P.S. Burden of liver diseases in the world. J. Hepatol. 2019;70(1):151–171. DOI: 10.1016/j.jhep.2018.09.014
2. Rumgay H., Arnold M., Ferlay J., Lesi O. et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 2022;77(6):1598–1606. DOI: 10.1016/j.jhep.2022.08.021
3. Asrani S.K., Devarbhavi H., Eaton J., Kamath P.S. Burden of liver diseases in the world. J. Hepatol. 2019;70(1):151–71. DOI: 10.1016/j.jhep.2018.09.014
4. Pimpin L., Cortez-Pinto H., Negro F., Corbould E. et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J. Hepatol. 2018;69(3):718–35. DOI: 10.1016/j.jhep.2018.05.011
5. Sheu M.J., Liang F.W., Lin C.Y., Lu T.H. Changes in liver-related mortality by etiology and sequelae: underlying versus multiple causes of death. Popul. Health Metr. 2021;19(1):22. DOI: 10.1186/s12963-021-00249-0
6. Asrani S.K., Devarbhavi H., Eaton J., Kamath P.S. Burden of liver diseases in the world. J. Hepatol. 2019;70(1):151–71. DOI: 10.1016/j.jhep.2018.09.014
7. Sepanlou S.G., Safi ri S., Bisignano C., Ikuta K.S. et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2020;5(3):245–66. DOI: 10.1016/S2468-1253(19)30349-8
8. Nasr P., Ndegwa N., von Seth E., Ludvigsson J.F., Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019. Journal of Hepatology. 2022;1:S82–S82. DOI: 10.1016/S0168-8278(22)00558-X
9. Ye F., Zhai M., Long J., Gong Y. et al. The burden of liver cirrhosis in mortality: Results from the global burden of disease study. Frontiers in Public Health. 2022;10:909455. DOI: 10.3389/fpubh.2022.909455
10. Sarin S.K., Kumar M., Eslam M., George J. et al. Liver diseases in the Asia-Pacifi c region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 2020;5(2):167–228. DOI: 10.1016/S2468-1253(19)30342-5
11. Samorodskaya I.V. Cause-of-death coding as a factor infl uencing mortality rates from individual causes. Vrach. 2021;32(5):21–27. (In Russian). DOI: 10.29296/25877305-2021-05-04
12. Gallaher J.R., Charles A. Acute Cholecystitis: A Review. JAMA. 2022;327(10):965–975. DOI: 10.1001/jama.2022.2350
13. Li S., Guizzetti L., Ma C., Shaheen A.A., Dixon E., Ball C., Wani S., Forbes N. Epidemiology and Outcomes of Symptomatic Cholelithiasis and Cholecystitis in the USA: Trends and Urban-Rural Variations. J. Gastrointest. Surg. 2023 May;27(5):932-944. DOI: 10.1007/s11605-023-05604-0
14. Yoshiji H., Nagoshi S., Akahane T., Asaoka Y., Ueno Y., Ogawa K., Kawaguchi T., Kurosaki M., Sakaida I., Shimizu M., Taniai M., Terai S., Nishikawa H., Hiasa Y., Hidaka H., Miwa H., Chayama K., Enomoto N., Shimosegawa T., Takehara T., Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J. Gastroenterol. 2021;56(7):593–619. DOI: 10.1007/s00535-021-01788-x
15. Singal A.K., Bataller R., Ahn J., Kamath P.S., Shah V.H. ACG clinical guideline: alcoholic liver disease. Am. J. Gastroenterol. 2018;113(2):175–194. DOI: 10.1038/ajg.2017.469
16. Coppola N., Onorato L., Sagnelli C., Sagnelli E. et al. Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis. Medicine (Baltimore). 2016;95(30):e4311. DOI: 10.1097/MD.0000000000004311
17. Drapkina O.M., Samorodskaia I.V., Kakorina E.P. Variability in regional mortality rates. Profi lakticheskaya Meditsina. 2019;22(6):2833. (In Russian) DOI: 10.17116/profmed20192206228
18. Quantifying cause-related mortality by weighting multiple causes of death. Bull. World Health Organ. 2016;94(12):870–879.
19. Golabi P., Paik J.M., Eberly K., de Avila L. et al. Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C. Ann. Hepatol. 2022;27(1):100556. DOI: 10.1016/j.aohep.2021.100556
20. Paik J.M., Golabi P., Younossi Y., Mishra A., Younossi Z.M. Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of NAFLD. Hepatology. 2020;72(5):1605–1616. DOI: 10.1002/hep.31173
21. Marques P., Francisco V., Martínez-Arenas L., Carvalho-Gomes Â., Domingo E., Piqueras L., Berenguer M., Sanz M.J. Overview of cellular and soluble mediators in systemic infl ammation associated with non-alcoholic fatty liver disease. Int. J. Mol. Sci. 2023;24(3):2313. DOI: 10.3390/ijms24032313.
22. Hua Z., Liu R., Chen Y., Liu G., Li C., Song Y., Cao Z., Li W., Li W., Lu C., Liu Y. Contamination of afl atoxins induces severe hepatotoxicity through multiple mechanisms. Front Pharmacol. 2021;11:605823. DOI: 10.3389/fphar.2020.605823
23. Wang J., Huang R., Liu J., Lai R., Liu Y., Zhu C., Qiu Y., He Z., Yin S., Chen Y., Yan X., Ding W., Zheng Q., Li J., Wu C. A novel non-invasive model for the prediction of advanced liver fi brosis in chronic hepatitis B patients with NAFLD. J. Viral Hepat. 2023; 30(4):287-296. DOI: 10.1111/jvh.13808
24. Tapper E.B., Parikh N.D. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ. 2018;362:k2817. DOI: 10.1136/bmj.k2817
25. McCall В. Shock as death certifi cates cite obesity in < 10% of relevant cases. URL: https://www.medscape.com/viewarticle/936778
26. Allison M.E.D., Verne J., Bernal W., Clayton M., Cox S., Dhanda A., Dillon J.F., Ferguson J., Foster G., Gilmore I., Hebditch V., Jones R., Masson S., Oates B., Richardson P., Sinclair J., Wendon J., Wood D. Deaths from alcohol-related liver disease in the UK: an escalating tragedy. Lancet. 2023;401(10375):418–420. DOI: 10.1016/S0140-6736(22)02583-1
27. Kim D., Alshuwaykh O., Dennis B.B., Cholankeril G. et al. Trends in etiology-based mortality from chronic liver disease before and during COVID-19 pandemic in the United States. Clin. Gastroenterol. Hepatol. 2022;20(10):2307-2316.e3. DOI: 10.1016/j.cgh.2022.05.045.
Review
For citations:
Samorodskaya I.V., Afanasenkova T.E. Dynamics and variability of regional mortality rates from liver and biliary tract diseases in the period from 2019 to 2021. Clinical Medicine (Russian Journal). 2023;101(9-10):489-495. (In Russ.) https://doi.org/10.30629/0023-2149-2023-101-9-10-489-495
Views:
837
Email this article 